CD274 and neoplasm: Moreover, low doses of prexasertib predominantly inhibited tumor growth and produced higher PD-L1 in immune-competent mice compared with immune-deficient mice, indicating that CHK1i induced a stronger immune response in the immune-proficient tumor microenvironment.